sarcoma

Summary

Summary: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.

Top Publications

  1. ncbi Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity
    Marco Fiore
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, Milan, 20133, Italy
    Ann Surg Oncol 13:110-7. 2006
  2. pmc Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
    Jordi Barretina
    Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    Nat Genet 42:715-21. 2010
  3. pmc Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma
    Birgit Lohberger
    Department of Orthopaedic Surgery, Medical University of Graz, Graz, Austria
    PLoS ONE 7:e43664. 2012
  4. doi Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
    Winette T A van der Graaf
    Radboud University Medical Centre, Department of Medical Oncology, Nijmegen, Netherlands
    Lancet 379:1879-86. 2012
  5. ncbi Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
  6. ncbi Diagnosis of gastrointestinal stromal tumors: A consensus approach
    Christopher D M Fletcher
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston MA 02115, USA
    Hum Pathol 33:459-65. 2002
  7. pmc High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A
    Sapna Vijayakumar
    Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer Cell 19:601-12. 2011
  8. doi Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
    Richard Quek
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:871-9. 2011
  9. ncbi Soft-tissue sarcomas in adults
    Matthew A Clark
    Sarcoma Unit, the Royal Marsden Hospital National Health Service Foundation Trust, London
    N Engl J Med 353:701-11. 2005
  10. doi The insulin-like growth factor system and sarcomas
    Bart Rikhof
    Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, The Netherlands
    J Pathol 217:469-82. 2009

Detail Information

Publications388 found, 100 shown here

  1. ncbi Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity
    Marco Fiore
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, Milan, 20133, Italy
    Ann Surg Oncol 13:110-7. 2006
    We explored the outcome of patients with primary adult soft tissue sarcoma (STS) of the extremities undergoing re-excision after previous unplanned surgery.
  2. pmc Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
    Jordi Barretina
    Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    Nat Genet 42:715-21. 2010
    ..Our study yields a detailed map of molecular alterations across diverse sarcoma subtypes and suggests potential subtype-specific targets for therapy.
  3. pmc Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma
    Birgit Lohberger
    Department of Orthopaedic Surgery, Medical University of Graz, Graz, Austria
    PLoS ONE 7:e43664. 2012
    ..assay and fluorescence-activated cell sorting (FACS) analysis to isolate ALDH1(high) cells from five human sarcoma cell lines and one primary chordoma cell line. ALDH1(high) cells range from 0.3% (MUG-Chor1) to 4...
  4. doi Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
    Winette T A van der Graaf
    Radboud University Medical Centre, Department of Medical Oncology, Nijmegen, Netherlands
    Lancet 379:1879-86. 2012
    ..tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic ..
  5. ncbi Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
    ..agent and the combination of gemcitabine and docetaxel have activity in patients with metastatic soft tissue sarcoma. To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic ..
  6. ncbi Diagnosis of gastrointestinal stromal tumors: A consensus approach
    Christopher D M Fletcher
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston MA 02115, USA
    Hum Pathol 33:459-65. 2002
    ....
  7. pmc High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A
    Sapna Vijayakumar
    Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer Cell 19:601-12. 2011
    ..We show here that 50% of human sarcomas (n = 45) and 65% of sarcoma cell lines (n = 23) of diverse histological subtypes exhibit upregulated autocrine canonical Wnt signaling...
  8. doi Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
    Richard Quek
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:871-9. 2011
    ..Pharmacokinetics and preliminary antitumor effects of the combination were evaluated...
  9. ncbi Soft-tissue sarcomas in adults
    Matthew A Clark
    Sarcoma Unit, the Royal Marsden Hospital National Health Service Foundation Trust, London
    N Engl J Med 353:701-11. 2005
  10. doi The insulin-like growth factor system and sarcomas
    Bart Rikhof
    Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, The Netherlands
    J Pathol 217:469-82. 2009
    ..growth factor (IGF) signalling system in the cellular transformation and progression of several types of sarcoma, including rhabdomyosarcoma, synovial sarcoma, leiomyosarcoma, Ewing's sarcoma and osteosarcoma...
  11. ncbi Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma
    Jan Ahlén
    Department of Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden
    Clin Cancer Res 11:206-16. 2005
    ..To evaluate known and suggested prognostic markers, especially insulin-like growth factor type 1 receptor (IGF-1R), in highly malignant soft tissue sarcomas (STS)...
  12. pmc Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing
    Françoise Ducimetière
    Universite de Lyon, Cancer Centre Léon Bérard, EA 4129, Lyon, France
    PLoS ONE 6:e20294. 2011
    The exact overall incidence of sarcoma and sarcoma subtypes is not known...
  13. doi Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases
    Panta Rouhani
    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7231, USA
    Cancer 113:616-27. 2008
    ..Cutaneous soft tissue sarcomas (CSTS) are a heterogeneous group of mesenchymal neoplasms. To the authors' knowledge, no prior large, population-based study has focused on CSTS...
  14. doi NVP-BEZ235 as a new therapeutic option for sarcomas
    Maria C Manara
    Laboratorio di Ricerca Oncologica, Istituto Ortopedico Rizzoli, Bologna, Italy
    Clin Cancer Res 16:530-40. 2010
    To evaluate the in vitro and in vivo effects of NVP-BEZ235, a dual pan-phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor in the three most common musculoskeletal tumors (osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma).
  15. ncbi CCNU for the treatment of dogs with histiocytic sarcoma
    Katherine A Skorupski
    Departments of Clinical Studies, Matthew J Ryan Veterinary Hospital, University of Pennsylvania Philadelphia, USA
    J Vet Intern Med 21:121-6. 2007
    Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy of chemotherapy against this disease is unknown...
  16. doi Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis
    Marianne Kraus
    Department of Medicine II, University of Tubingen, Tubingen, Germany
    Mol Cancer Ther 7:1940-8. 2008
    ..Most solid malignancies such as sarcoma, by contrast, are poorly bortezomib sensitive and display low levels of ER stress...
  17. pmc MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century
    Igor Matushansky
    Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Expert Rev Anticancer Ther 9:1135-44. 2009
    ..Originally characterized as a morphologically unique soft-tissue sarcoma subtype of unclear etiology in 1963, with a following 15 years of research only to conclude that "the issue of ..
  18. doi Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
    Patrick Schoffski
    University Hospitals Leuven, Catholic University Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium
    Lancet Oncol 12:1045-52. 2011
    ..We assessed the activity and safety of eribulin in four strata of patients with different types of soft-tissue sarcoma.
  19. doi Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years
    N Penel
    European Organisation for Research and Treatment of Cancer Headquarters, EORTC, Brussels, Belgium
    Ann Oncol 22:1266-72. 2011
    The prognosis of advanced soft tissue sarcoma remains poor. Many phase II trials investigating new regimens have been published in the last 10 years.
  20. pmc Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report
    Jong Sil Lee
    Department of Pathology, College of Medicine, Gyeongsang National University, Jinju, Korea
    J Korean Med Sci 21:577-80. 2006
    Langerhans cell sarcoma (LCS) is a neoplastic proliferation of Langerhans cells that have overtly malignant cytologic features...
  21. ncbi p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion
    Gustavo Baldassarre
    Oncologia Sperimentale 2, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano 33081, Italy
    Cancer Cell 7:51-63. 2005
    ..This study provides a functional link between proliferation and invasion of tumor cells based on diverse activities of p27(kip1) in different subcellular compartments...
  22. doi Uterine sarcomas: a review
    Emanuela D'Angelo
    Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Sant Antoni M Claret, 167, 08025 Barcelona, Spain
    Gynecol Oncol 116:131-9. 2010
    ..Currently, there is no consensus on risk factors for adverse outcome. This review summarizes the available clinicopathological data on uterine sarcomas classified by the WHO diagnostic criteria...
  23. ncbi Sarcoma as a second malignancy after treatment for breast cancer
    Johnny Yap
    Department of Radiation Oncology, Wayne State University School of Medicine, Detroit, MI, USA
    Int J Radiat Oncol Biol Phys 52:1231-7. 2002
    ..neoplasms in breast cancer patients have been limited by the numbers of patients and relatively low incidence of sarcoma. Using data from the Surveillance, Epidemiology and End Results registries, we evaluated the influence of ..
  24. doi Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 620
    Stefan Sleijfer
    Dept of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    J Clin Oncol 27:3126-32. 2009
    PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and platelet-derived growth factor receptor, was explored in ..
  25. ncbi Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
    D Malkin
    Division of Molecular Genetics, Massachusetts General Hospital Cancer Center, Charlestown 02129
    Science 250:1233-8. 1990
    ..The frequency of germ line p53 mutations can now be examined in additional families with LFS, and in other cancer patients and families with clinical features that might be attributed to the mutation...
  26. ncbi Opportunities for improving the therapeutic ratio for patients with sarcoma
    Jay S Wunder
    University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
    Lancet Oncol 8:513-24. 2007
    ..Limb-sparing surgery delivered at specialised sarcoma centres as part of a multidisciplinary approach has become the standard treatment for most patients and usually ..
  27. pmc Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
    David Olmos
    The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK
    Lancet Oncol 11:129-35. 2010
    ..Preclinical data suggest a dependence on insulin-like growth-factor signalling for sarcoma subtypes, including Ewing's sarcoma, and early reports show antitumour activity of IGF-1R-targeting drugs in ..
  28. pmc MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells
    Jenny M Kreahling
    Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Mol Cancer Ther 11:174-82. 2012
    ..Here, we studied the cytotoxic effect of MK1775 in various sarcoma cell lines and patient-derived tumor explants ex vivo...
  29. ncbi Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
    A Le Cesne
    Department of Medicine, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Oncol 23:576-84. 2005
    ..5 mg/m(2) as a 24-hour continuous infusion every 3 weeks in patients with pretreated advanced soft tissue sarcoma.
  30. pmc Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance
    Mary A Zimmerman
    Department of Biochemistry and Molecular Biology, Georgia Health Sciences University, Augusta, Georgia 30912, USA
    Cancer Res 72:4724-32. 2012
    ..Using a murine model of soft tissue sarcoma (STS), we show that disruption of the IFN effector molecule IRF8 decreases pSTAT1 and increases uSTAT1 in STS ..
  31. doi Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma
    Jason L Hornick
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 33:542-50. 2009
    ..Immunostaining for INI1 can be used to confirm the diagnosis of ES in the appropriate context. Loss of INI1 expression may also be helpful to distinguish epithelioid MPNST from metastatic melanoma in a subset of cases...
  32. doi High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, Viale Filopanti 22, University of Bologna, 40126 Bologna, Italy
    Eur J Cancer 46:659-68. 2010
    ..Metastatic spread of a panel of human sarcoma cell lines was studied in double knockout Rag2(-/-);gammac(-/-) mice in comparison with NK-depleted nude mice...
  33. ncbi The biology behind mTOR inhibition in sarcoma
    Xiaolin Wan
    Molecular Oncology Section, Pediatric Oncology Branch, Building 10, Room CRC 1W 3816, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1928, USA
    Oncologist 12:1007-18. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  34. pmc Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy
    David T Vistica
    Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    J Pediatr Hematol Oncol 31:561-70. 2009
    In vivo growth of alveolar soft part sarcoma (ASPS) was achieved using subcutaneous xenografts in sex-matched nonobese diabetic severe combined immunodeficiency mice...
  35. doi Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside
    David Olmos
    Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
    Cancer J 16:183-94. 2010
    ..Two decades have elapsed since insulin-like growth factor-1 receptor (IGF-1R) signaling was initially implicated in sarcoma biology to the first clinical experience of IGF-1R blockade in sarcoma...
  36. pmc The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma
    Raushan T Kurmasheva
    Departments of Molecular Pharmacology, Biostatistics, and Pathology, St Jude Children s Research Hospital, Memphis, TN38105, USA
    Cancer Res 69:7662-71. 2009
    ..CP-751,871, a human antibody that blocks IGF-1R ligand binding, alone and in combination with rapamycin against sarcoma cell lines in vitro and xenograft models in vivo...
  37. ncbi Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience
    Patrick Van Winkle
    Childrens Hospital of Los Angeles, Los Angeles, California, USA
    Pediatr Blood Cancer 44:338-47. 2005
    ..We determined the overall response rate (ORR) and overall survival (OS) of children with recurrent/refractory sarcomas who were given ifosfamide, carboplatin, and etoposide (ICE) in three Children's Cancer Group (CCG) phase I/II trials...
  38. pmc Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers
    Andrew H Beck
    Pathology Department, Stanford University Medical Center, Stanford, CA 94305, USA
    Virchows Arch 456:141-51. 2010
    ..In the past decade, gene expression profiling has been applied to sarcomas to facilitate understanding of sarcoma pathogenesis and to identify diagnostic, prognostic, and predictive markers...
  39. pmc Ether à go-go potassium channel expression in soft tissue sarcoma patients
    Fernanda Mello de Queiroz
    Divisão de Farmacologia, Coordenação de Pesquisa, Instituto Nacional do Cancer, Rio de Janeiro, Brazil
    Mol Cancer 5:42. 2006
    ..Our purpose was to determine the frequency of expression of Eag1 in soft tissue sarcoma and its potential clinical implications.
  40. ncbi Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities
    Margaret M Roebuck
    Department of Musculoskeletal Science, University of Liverpool, Liverpool, England
    Am J Clin Pathol 123:405-14. 2005
    ..The activation of endothelial MMP-2 linked to widespread MMP-14 expression provides a mechanism for sarcomas to modulate their matrix and facilitate angiogenesis...
  41. ncbi Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    Jaap Verweij
    Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    Lancet 364:1127-34. 2004
    ..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
  42. ncbi Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
    A Yovine
    Hopital St Louis, Unité d Oncologie Médicale, 1 av Claude Vellefaux, 75010 Paris, France
    J Clin Oncol 22:890-9. 2004
    A multicenter phase II study evaluating efficacy, safety, and pharmacokinetics of ecteinascidin-743 (ET-743) in pretreated advanced soft tissue sarcoma patients.
  43. ncbi Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad
    J Aidan Carney
    Department of Laboratory Medicine and Pathology Emeritus member, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Med Genet 108:132-9. 2002
    ..with an average age of 23 years from five unrelated families that manifested paraganglioma and gastric stromal sarcoma; the tumors were inherited in an apparent autosomal dominant manner, with incomplete penetrance...
  44. ncbi Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time
    Jurgen Weitz
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:2719-25. 2003
    The objective of this study was to define whether survival of patients with extremity soft tissue sarcoma (STS), stratified for known risk factors, has improved over the last 20 years.
  45. ncbi MicroRNA expression signature of human sarcomas
    S Subramanian
    Department of Pathology, Stanford University, Stanford, CA 94305, USA
    Oncogene 27:2015-26. 2008
    ..Our data show that different histological types of sarcoma have distinct miRNA expression patterns, reflecting the apparent lineage and differentiation status of the tumors...
  46. pmc Phenoxy herbicides and chlorophenols: a case control study on soft tissue sarcoma and malignant lymphoma
    J G Smith
    Statistical Centre, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Br J Cancer 65:442-8. 1992
    A case control study on patients with soft tissue sarcoma and malignant lymphoma was undertaken to test whether there was any association between these diseases and past exposure to chlorinated phenoxy acid herbicides or chlorophenols...
  47. ncbi Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
    D M Brizel
    Department of Radiation Oncology, Duke University Comprehensive Cancer Center, Durham, North Carolina, 27710, USA
    Cancer Res 56:941-3. 1996
    ..was performed to explore the relationship between tumor oxygenation and treatment outcome in human soft tissue sarcoma. Twenty-two patients with nonmestastatic, high-grade, soft tissue sarcomas underwent preoperative irradiation and ..
  48. ncbi Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 6007, USA
    Int J Cancer 100:623-6. 2002
    Dermatofibrosarcoma protuberans (DFSP) is a rare superficial sarcoma usually affecting the trunk, with significant risk of local recurrence...
  49. pmc Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma
    Brian P Rubin
    Department of Anatomic Pathology, Taussig Cancer Center and Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cancer Cell 19:177-91. 2011
    ..prenatal or postnatal myogenic cell of origin, we demonstrate that eRMS and undifferentiated pleomorphic sarcoma (UPS) lie in a continuum, with satellite cells predisposed to giving rise to UPS...
  50. pmc Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma
    Ivaylo Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, California, United States of America
    PLoS ONE 7:e37239. 2012
    ..In this study we describe the establishment of an in vivo model of canine soft tissue sarcoma (CSTS) using the new isolated cell line STSA-1 and the analysis of the virus-mediated oncolytic and immunological ..
  51. ncbi Adaptive immunity maintains occult cancer in an equilibrium state
    Catherine M Koebel
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Nature 450:903-7. 2007
    ..These results reveal that, in addition to destroying tumour cells and sculpting tumour immunogenicity, the immune system of a naive mouse can also restrain cancer growth for extended time periods...
  52. ncbi A spatially and temporally restricted mouse model of soft tissue sarcoma
    David G Kirsch
    Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
    Nat Med 13:992-7. 2007
    ..To explore mechanisms of sarcoma pathogenesis, we have generated a mouse model of soft tissue sarcoma...
  53. ncbi Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy
    O Hans Iwenofu
    Department of Pathology, Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA
    Mod Pathol 21:231-7. 2008
    ..The level of phosphorylated S6 ribosomal protein expression was predictive of early tumor response to the mTOR inhibitor, suggesting that this is a promising new predictive sarcoma marker for targeted mTOR inhibitor therapy.
  54. doi Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
    Stefan Sleijfer
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 46:72-83. 2010
    ..As ifosfamide is frequently applied in first line systemic therapy, we aimed to establish prognostic and predictive factors for outcome to ifosfamide-based therapy...
  55. ncbi Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity
    S Delaloge
    , Villejuif, France
    J Clin Oncol 19:1248-55. 2001
    PURPOSE: To report the activity of the chemotherapeutic agent ecteinascidin-743 (ET-743) in advanced pretreated sarcoma patients observed during a phase I study and a named-patient basis, compassionate use program...
  56. ncbi Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas
    Z A Khatib
    Department of Experimental Oncology and Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105
    Cancer Res 53:5535-41. 1993
    ..which are frequently amplified in human sarcomas, we analyzed CDK4 copy number and expression in a panel of sarcoma cell lines...
  57. ncbi Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma
    Tsukasa Sotobori
    Department of Orthopedics, Osaka University Graduate School of Medicine, Yamada oka, Suita, Japan
    Cancer 106:2233-40. 2006
    ..The objective of the current study was to evaluate the prognostic significance of WT1 mRNA expression in patients with soft tissue sarcoma.
  58. ncbi Mechanisms of sarcoma development
    Lee J Helman
    Molecular Oncology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, Room 13N240, MSC 1928, Bethesda, Maryland 20892 1928, USA
    Nat Rev Cancer 3:685-94. 2003
    ..It is likely that this approach will lead to continued refinements in classification and treatment of these tumours...
  59. doi Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma
    A I Sahora
    The Oncology Service, LLC, Washington, DC, USA
    J Vet Intern Med 26:1169-76. 2012
    ..Exposure to anti-angiogenic thrombospondin-1 (TSP-1) mimetic peptides (MPs) has resulted in sporadic anti-tumor activity in humans and dogs...
  60. doi A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion
    Gaelle Pierron
    Institut Curie, Unité de Génétique Somatique Centre Hospitalier, Paris, France
    Nat Genet 44:461-6. 2012
    The identification of subtype-specific translocations has revolutionized the diagnostics of sarcoma and has provided new insight into oncogenesis...
  61. pmc Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome
    Janet F Eary
    Division of Nuclear Medicine, Departments of Radiology and Orthopedic Surgery, University of Washington, Seattle, Washington, USA
    J Nucl Med 49:1973-9. 2008
    ..This study presents data to support the hypothesis that a new heterogeneity-analysis algorithm applied to (18)F-FDG PET images of tumors in patients is predictive of patient outcome...
  62. pmc Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients
    J Szkandera
    Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
    Br J Cancer 109:2316-22. 2013
    ..The aim of the present study was to validate the prognostic value of pre-operative plasma CRP levels on clinical outcome in a large cohort of soft-tissue sarcoma (STS) patients.
  63. pmc Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma
    Andrew D Kelly
    Division of Hematology Oncology, Sarcoma Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e25357. 2011
    ..Our study supports the notion that reliable and broadly informative metabolomic data may be acquired from FFPE soft tissue sarcoma specimens, a finding that is likely to be extended to other malignancies.
  64. pmc Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507
    Emmy D G Fleuren
    Departments of Medical Oncology and Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 17:7693-703. 2011
    ....
  65. doi Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas
    Waddah B Al-Refaie
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77203 1402, USA
    Cancer 112:1821-6. 2008
    ..This study was performed to determine the outcomes of patients who underwent aggressive therapy, including lymphadenectomy in patients with LN metastasis from ESTS...
  66. ncbi Epithelioid sarcoma: Still an only surgically curable disease
    Sebastiaan A H J de Visscher
    Department of Surgical Oncology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands
    Cancer 107:606-12. 2006
    Epithelioid sarcoma is a rare soft tissue sarcoma with a known high propensity for locoregional recurrence and distant metastases...
  67. ncbi Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis
    Frank Bartel
    Institute of Pathology, Faculty of Medicine, University of Halle Wittenberg, Halle Saale, Germany
    Int J Cancer 117:469-75. 2005
    ..In summary, our data indicate that both the overexpression of the HDMX-S transcript as well as HDMX gene amplification are important prognostic markers for STS...
  68. ncbi Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas
    Akira Nagamatsu
    Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama 641 8509, Japan
    Oncol Rep 23:1069-76. 2010
    ..In conclusion, FDG-PET is useful for diagnosing uterine sarcomas, while FDG-PET combined with serum LDH is useful for diagnosing LMS. Immunohistochemical examination of GLUT-1 confirmed the high FDG uptake in LMS patients...
  69. doi A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma
    Chao Zhang
    Institute of Combined Injury, State Key Laboratory of Trauma, Burns and Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, 30 Gaotanyan Road, Chongqing 400038, China
    Biomaterials 31:9535-43. 2010
    ..PP2A inhibition activity but without apparent toxicity, greatly enhanced the effectiveness of the standard anti-sarcoma chemotherapeutic agent, doxorubicin (DOX), in the xenograft growth inhibition and lung metastases prevention of ..
  70. doi Molecular genetics of sarcomas: applications to diagnoses and therapy
    Junya Toguchida
    Department of Tissue Regeneration, Institute for Frontier Medical Sciences, Kyoto University
    Cancer Sci 100:1573-80. 2009
    ....
  71. ncbi Detection and grading of soft tissue sarcomas of the extremities with (18)F-3'-fluoro-3'-deoxy-L-thymidine
    David C P Cobben
    Department of Surgical Oncology, Groningen University Hospital, Groningen, The Netherlands
    Clin Cancer Res 10:1685-90. 2004
    The aim of the study was to investigate the feasibility of (18)F-3'-fluoro-3'-deoxy-L-thymidine positron emission tomography (FLT-PET) for the detection and grading of soft tissue sarcoma (STS).
  72. ncbi Prognosis of lymph node metastasis in soft tissue sarcoma
    Kasim A Behranwala
    Sarcoma and Melanoma Unit, Royal Marsden NHS Trust, 203 Fulham Road, London SW3 6JJ, UK
    Ann Surg Oncol 11:714-9. 2004
    We defined the tumor characteristics and prognosis of patients with regional lymph node metastasis (RLNM) from soft tissue sarcoma.
  73. doi Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model
    Xiaojun Yan
    Ningbo University, Key Laboratory of Applied Marine Biotechnology, Ministry of Education, Ningbo, Zhejiang 315211, China
    Eur J Pharm Sci 43:251-9. 2011
    ..In order to verify these two effects in animal model and to identify action mechanisms, we established a sarcoma mice model, and treated mice with fascaplysin for 10 days...
  74. doi Appraising the current role of chemotherapy for the treatment of sarcoma
    David R D'Adamo
    Sarcoma and Bone Cancer Treatment Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Semin Oncol 38:S19-29. 2011
    ..They can be grouped into two general categories: soft tissue sarcoma (STS) and primary bone sarcoma, which are treated differently...
  75. doi The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity
    Roi Dagan
    Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA
    Cancer 118:3199-207. 2012
    Marginal excision of soft tissue sarcoma (STS), defined as resection through the tumor pseudocapsule or surrounding reactive tissue, increases the likelihood of local recurrence and necessitates re-excision or postoperative radiation...
  76. doi A novel combined radiological method for evaluation of the response to chemotherapy for primary bone sarcoma
    Shinji Miwa
    Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa, Japan
    J Surg Oncol 106:273-9. 2012
    In the treatment of bone sarcoma, evaluation of chemotherapeutic effects is extremely important...
  77. doi Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas
    Jan P Deroose
    Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The Netherlands
    J Clin Oncol 29:4036-44. 2011
    ..This study reports the long-term results of 231 TM-ILPs for locally advanced extremity STS...
  78. pmc Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches
    Richard F Riedel
    Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 118:1474-85. 2012
    ..This article provides an overview of current systemic therapies for patients with advanced STS and discusses ongoing efforts designed to improve patient outcomes through the use of novel therapeutic agents and treatment strategies...
  79. doi Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas
    John T Mullen
    Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Cancer 118:3758-65. 2012
    ..We report the long-term follow-up data on 48 patients treated with this regimen compared to an historical matched-control patient population...
  80. doi Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era
    Faisal G Bakaeen
    Department of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Tex 77030, USA
    J Thorac Cardiovasc Surg 137:1454-60. 2009
    ..Primary cardiac sarcomas are rare tumors carrying poor prognosis. Resection remains the primary therapy. Especially in recent years, chemotherapy and radiation have been used adjunctively...
  81. ncbi Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
    R Garcia-Carbonero
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Harvard Medical School, Shields Warren Bldg, Room G530, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:1480-90. 2004
    ....
  82. doi Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations
    Stine H Kresse
    Department of Tumor Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Cancer 118:558-70. 2012
    ..Human tumors transplanted into immunodeficient mice (xenografts) are good preclinical models, and it is important to identify possible systematic changes during establishment and passaging in mice...
  83. pmc Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group
    Joseph G Pressey
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 57:930-8. 2011
    ..A previous report utilizing in situ hybridization has provided initial evidence for the expression of Hh targets GLI1 and PTCH in RMS tumors...
  84. doi Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival
    Alessandro Gronchi
    Department of Surgery, Istituto Nazionale Tumori, Milan, Italy
    Ann Surg 251:506-11. 2010
    ..To improve understanding of what is adequate in local treatment of extremity soft tissue sarcomas (ESTS), to maximize the ratio between local control, limb preservation and prognosis...
  85. pmc Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 235:424-34. 2002
    To define the significance of positive microscopic resection margins in a large cohort treated for soft tissue sarcoma.
  86. ncbi Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines
    Hiromasa Fujii
    Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara 634 8521, Japan
    Int J Oncol 34:1381-6. 2009
    ..The aim of the current study was to demonstrate whether the human sarcoma cell lines, osteosarcoma MG63, Ewing's sarcoma HTB166, fibrosarcoma HT1080, possess the stem-like properties ..
  87. doi Diagnosis and management of primary breast sarcoma
    Sammy Al-Benna
    Operative Reference Centre for Soft Tissue Sarcoma, BG University Hospital Bergmannsheil, Ruhr University Bochum, Burkle de la Camp Platz 1, 44789 Bochum, Nordrhein Westfalen, Germany
    Breast Cancer Res Treat 122:619-26. 2010
    Primary sarcoma of the breast is an extremely rare and heterogeneous disease. The rarity of this tumour limits most studies to small retrospective case reviews and case reports and has made clinicopathological study difficult...
  88. ncbi Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression
    Kebin Liu
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1402, USA
    Cancer Res 65:4376-88. 2005
    ..Thus, in this model, Fas-mediated cytotoxicity, in concert with IFN-gamma-regulated gene expression, mechanistically constituted significant determinants of immune selection of ATV in vivo...
  89. pmc Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics
    Gaëlle Pérot
    Institut Curie, Genetics and Biology of Cancers, Paris, France
    Am J Pathol 177:2080-90. 2010
    ..we could not detect p14 protein suggests that other p14 functions, independent of p53, could be implicated in sarcoma oncogenesis...
  90. pmc Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?
    Rebecca A Gladdy
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1209, New York, NY 10065, USA
    J Clin Oncol 28:2064-9. 2010
    ..DSS in patients with primary RAS is significantly worse compared with sporadic STS independent of sarcoma histologic type.
  91. doi Histology-driven chemotherapy in soft tissue sarcomas
    Michelle Scurr
    Sarcoma Unit, Royal Marsden Hospital, London, UK
    Curr Treat Options Oncol 12:32-45. 2011
    ..and ifosfamide are the two chemotherapy drugs that have consistently demonstrated activity in "soft tissue sarcoma" (STS)...
  92. doi Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma
    Wenhong Ren
    Department of Surgical Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:5466-75. 2008
    Soft tissue sarcoma (STS) is a rare heterogeneous malignancy. Overall survival has been stagnant for decades, primarily because systemic therapies are ineffective versus metastases, the leading cause of STS lethality...
  93. doi Trends in survival for patients with metastatic soft-tissue sarcoma
    Antoine Italiano
    Department of Medical Oncology, Bergonie Institute, Bordeaux, France
    Cancer 117:1049-54. 2011
    The objective of this study was to determine whether the overall survival of patients with metastatic soft tissue sarcoma (STS) has improved over the last 20 years.
  94. doi Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models
    Rachel M Squillace
    ARIAD Pharmaceuticals, Inc, 26 Landsdowne Street, Cambridge, MA 02139, USA
    Mol Cancer Ther 10:1959-68. 2011
    ..rapamycin analogue that potently inhibits mTOR and has shown significant activity in patients with metastatic sarcoma and endometrial cancer, two diseases where high unmet need remains...
  95. ncbi Time dependence of prognostic factors for patients with soft tissue sarcoma: a Scandinavian Sarcoma Group Study of 338 malignant fibrous histiocytomas
    Jacob Engellau
    Department of Oncology, The Jubileum Institute, Lund University, Lund, Sweden
    Cancer 100:2233-9. 2004
    Prognostic factors for metastasis in soft tissue sarcoma govern decisions regarding adjuvant treatment. However, the significance of initial tumor-related prognostic factors over time is largely unknown.
  96. ncbi The outcomes and prognostic factors of patients with soft-tissue sarcoma
    P Kiatisevi
    Institute of Orthopaedic, Lerdsin General Hospital
    J Med Assoc Thai 89:334-42. 2006
    ..Occurrence of distant metastasis is associated with older age (> or = 60 years) and decreases disease-specific survival of the patients...
  97. pmc Molecular classification of soft tissue sarcomas and its clinical applications
    Shilpa Jain
    Department of Pathology, New York University School of Medicine, New York, NY, USA
    Int J Clin Exp Pathol 3:416-28. 2010
    ..Molecular genetics analyses have not only assisted in understanding the molecular mechanism in sarcoma pathogenesis but also demonstrated new relationships within different types of sarcomas leading to a more proper ..
  98. doi The clinical relevance of molecular genetics in soft tissue sarcomas
    José Luis Ordóñez
    Centro de Investigación del Cáncer IBMCC, Universidad de Salamanca CSIC, Spain
    Adv Anat Pathol 17:162-81. 2010
    ..showing relatively simple karyotypes and translocations, which originate gene fusions (eg, EWS-FLI1 in Ewing sarcoma) or point mutations (eg, c-kit in the gastrointestinal tumors) and (b) sarcomas showing unspecific gene ..
  99. ncbi Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy
    Gunar K Zagars
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:739-47. 2003
    To document the prognostic factors for survival of patients with soft-tissue sarcoma sustaining a first relapse after definitive treatment.
  100. pmc Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients
    H Taubert
    Department of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle Wittenberg, Halle, Germany
    Br J Cancer 102:731-7. 2010
    ..However, effects of co-expression of members of the uPA system in soft-tissue sarcoma (STS) patients at the protein level in both tumour tissue and serum have not been investigated yet.
  101. pmc Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1
    Arvind Ravi
    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Cancer Cell 21:848-55. 2012
    ..Furthermore, Dicer1 null cells from a sarcoma cell line, though depleted of miRNAs, are competent for tumor formation...

Research Grants72

  1. ROLE OF Rac AND REACTIVE OXYGEN SPECIES IN KAPOSI'S SARCOMA VIRAL ONCOGENESIS
    Enrique A Mesri; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Kaposi's sarcoma (KS), caused by the Kaposi's sarcoma-associated herpes virus (KSHV), is a major cancer associated with AIDS and a global health challenge...
  2. N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti
    Aquilur Rahman; Fiscal Year: 2010
    ..compound have shown the following promising characteristics: 1) It inhibits HSV-1, HSV-2, HSV-8 (Kaposi's Sarcoma Virus), as well as Vaccinia and Cowpox viruses 2) It is cytotoxic only in virus-infected cells 3) It is active ..
  3. N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti
    Aquilur Rahman; Fiscal Year: 2013
    ..manifested as oral HSV-1 and HSV-2 infections, genital HSV-2 infection and HSV-8 infection in Kaposi's sarcoma, which are prevalent in sexually transmitted diseases and immunosuppressed patients...
  4. Regulation of EBV Latency by EBNA1
    Paul M Lieberman; Fiscal Year: 2013
    ..protein, our studies will provide novel insight into the genome maintenance mechanisms shared by Kaposi's Sarcoma-Associated Herpesvirus (KSHV) LANA and human papillomavirus (HPV) E2 family members, as well as by cellular ..
  5. Regulation of KSHV Latency
    Paul M Lieberman; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): KSHV is the causative agent of Kaposi's sarcoma (KS) that occurs most frequently and severely in HIV-AIDS...
  6. ALS therapies and genomics for mutant TDP-43 and TLS/FUS
    Don W Cleveland; Fiscal Year: 2010
    ..that mutations in two strikingly similar DNA/RNA binding proteins, TAR DNA-binding protein (TDP-43) and Fused in sarcoma (FUS/TLS), are also primary causes of ALS...
  7. Herpesvirus protein kinases: Substrate recognition and pathway targeting.
    S Diane Hayward; Fiscal Year: 2013
    ..Epstein Barr Virus (EBV) and Kaposi's sarcoma associated herpesvirus (KSHV) are associated with AIDS related cancers and human cytomegalovirus (HCMV) with ..
  8. INTERNATIONAL HERPESVIRUS WORKSHOP
    Jay A Nelson; Fiscal Year: 2012
    ..The most recent human herpesvirus discovered (HHV-8 or KSHV) is associated with Kaposi's sarcoma in AIDS patients and other immunosuppressed persons and in other groups...
  9. Development of quantitative multiplex RNA in situ hybridization
    Thomas Tuschl; Fiscal Year: 2013
    ..As a proof of principle, we will apply the approach to improve sarcoma diagnosis through more accurate classification of small blue round cell tumors (SBRCTs) and spindle cell tumors (..
  10. Role of FUS in ALS
    Haining Zhu; Fiscal Year: 2013
    ..their mutation can lead to familial ALS, including two genes encoding RNA processing proteins TDP-43 and fused in sarcoma/translocated in liposarcoma (FUS/TLS). FUS is a ubiquitously expressed multi-domain RNA-binding protein...
  11. INTERNATIONAL HERPESVIRUS WORKSHOP
    Jay A Nelson; Fiscal Year: 2011
    ..The most recent human herpesvirus discovered (HHV-8 or KSHV) is associated with Kaposi's sarcoma in AIDS patients and other immunosupressed persons and in other groups...
  12. The role of cMET in satellite cells during muscle regeneration
    MICAH TAUBE WEBSTER; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma that occurs in children...
  13. Targeting Kinases that Phosphorylate the KSHV LANA Chromatin Binding Domain
    S Diane Hayward; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): KSHV is associated with the endothelial malignancy Kaposi sarcoma (KS) and the B cell cancers primary effusion lymphoma (PEL) and multicentric Castleman disease...
  14. Novel Compounds to Inactivate Oncogenic Fusion Proteins
    Jeffrey A Toretsky; Fiscal Year: 2013
    ..The Ewing's Sarcoma Family of Tumors (ESFT) contains a characteristic translocation, t(11:22), which leads to the oncogenic, fusion-..
  15. Epigenetic regulation of viral infection and replication by periodontal bacteria
    Fengchun Ye; Fiscal Year: 2013
    ..frequent infections by herpesviruses such as herpes simplex virus (HSV), Epstein Barr virus (EBV), and Kaposi sarcoma-associated herpesvirus (KSHV). The oral cavity is also a potential reservoir for latent HIV infection...
  16. STRUCTURAL STUDIES OF NUCLEOPROTEIN COMPLEXES
    Edward H Egelman; Fiscal Year: 2012
    ..HSV-1) ICP8, but will then be extended to related viral proteins, such as from Epstein Barr Virus and Kaposi Sarcoma Herpes Virus. III) Structural studies of F-pili, needed for bacterial conjugation, and filamentous bacteriophage...
  17. LANA and Cellular Gene Expression
    ROLF F RENNE; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Kaposi's sarcoma-associated herpesvirus (KSHV), also called Human herpesvirus type 8, is associated with Kaposi's sarcoma (KS) and two lymphoproliferative diseases: primary effusion ..
  18. INTERNATIONAL HERPESVIRUS WORKSHOP
    Jay A Nelson; Fiscal Year: 2013
    ..The most recent human herpesvirus discovered (HHV-8 or KSHV) is associated with Kaposi's sarcoma in AIDS patients and other immunosuppressed persons and in other groups...
  19. Assay Development for Inhibitors of KSHV
    Paul M Lieberman; Fiscal Year: 2010
    ..is to develop a robust high-throughput screen for identification of small molecule inhibitors of Kaposi's Sarcoma Associated Herpes virus (KSHV) and associated diseases...
  20. Modulation of histone deacetylase activity by a gammaherpesviral kinase
    Bryan C Mounce; Fiscal Year: 2013
    ..The human gammaherpesviruses Epstein-Barr Virus (EBV) and Kaposi's Sarcoma Associated Herpesvirus (KSHV) are associated with diverse diseases, including several cancers...
  21. Development of a novel vaccine for protection against gammaherpesvirus infection
    Blossom A Damania; Fiscal Year: 2010
    ..Infection with HIV causes a depletion of CD4+ T cells, which leads to immune suppression. Kaposi's sarcoma (KS), induced by KSHV, is the most common neoplasm seen among HIV infected individuals...
  22. Generation and Evaluation of KSHV VLPs as Vaccines
    GARY S contact HAYWARD; Fiscal Year: 2010
    ..Kaposi's sarcoma (KS) was one of the original defining opportunistic infections in the AIDS epidemic, when these highly angiogenic ..
  23. INTERNATIONAL HERPESVIRUS WORKSHOP
    Jay A Nelson; Fiscal Year: 2010
    ..The most recent human herpesvirus discovered (HHV-8 or KSHV) is associated with Kaposi's sarcoma in AIDS patients and other immunosupressed persons and in other groups...
  24. Beta-catenin is a molecular target of the Fanconi anemia core complex
    Kim Hien T Dao; Fiscal Year: 2013
    ..research experience began with her PhD training in the area of cancer biology and RAS signaling in human fibro sarcoma cell lines...
  25. Lysophosphatidic Acid in Oncogenesis
    Xianjun Fang; Fiscal Year: 2010
    ..The tumors include malignant lymphoma, lung adenocarcinoma, high-grade sarcoma, leiomyosarcoma, plasmacytoma and pilomatrixoma...
  26. Walleye Dermal Sarcooma Virus Accessory Protein Function
    Sandra L Quackenbush; Fiscal Year: 2012
    ..Walleye dermal sarcomas (WDS) are etiologically associated with the complex retrovirus, walleye dermal sarcoma virus (WDSV)...
  27. KSHV Lytic DNA Replication and its Control Mechanism
    Subhash C Verma; Fiscal Year: 2013
    ..gap in the understanding of molecular mechanism involved in regulating lytic DNA replication of Kaposi's sarcoma associated herpesvirus (KSHV) also known as Human Herpesvirus 8 (HHV8)...
  28. Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect
    Wolfgang W Scholz; Fiscal Year: 2012
    ..by applicant): This SBIR grant application for the clinical development of a novel vaccine to treat patients with sarcoma is based on a foundation of 30 years of studies at Memorial Sloan Kettering Cancer Center (MSKCC)...
  29. Conference Support for International Congress on Oncogenic Herpesviruses
    Paul M Lieberman; Fiscal Year: 2012
    ..and innovative in that it will serve as the first combined meeting of the International Workshop on Kaposi's Sarcoma-Associated Herpesvirus (KSHV) and Related Agents (15th Annual Meeting) and the International Symposium on Epstein-..
  30. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter J Houghton; Fiscal Year: 2012
    ..This approach appears to be highly effective against IGF-1-driven osteosarcoma and Ewing sarcoma xenograft models in vivo when rapamycin is combined with an antibody that blocks IGF-1 binding to the receptor...
  31. MOUSE MODELS FOR UNDERSTANDING HOST RESPONES TO INTRACELLULAR PATHOGENS
    Ellen A Robey; Fiscal Year: 2010
    ..Murine &Human cytomegalovirus, Murine herpes virus 68, Moloney Murine Leukemia Virus, Kaposi's Sarcoma Herpes Virus, Mouse Hepatitis Virus, Mouse Adeno Virus, Polyomavirus)...
  32. Ewing's Sarcoma Resistance to Immunity and Radiation
    Joyce C Solheim; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Ewing's sarcoma is a very painful cancer of the bone (and, more rarely, soft tissue) that strikes children and adolescents...
  33. ASSEMBLY OF THE HERPES SIMPLEX VIRUS CAPSID
    Jay C Brown; Fiscal Year: 2012
    ..effective against other herpesviruses including human cytomegalovirus, Epstein- Barr virus and Kaposi's sarcoma-associated herpesvirus...
  34. Cardiac Sparing Whole Lung IMRT in Children and Young Adults with Lung Metastases
    JOHN ANDREW KALAPURAKAL; Fiscal Year: 2012
    ..technique) is considered the standard of care for most patients with lung metastases from Wilms tumor, Ewing Sarcoma and rhabdomyosarcoma. Several studies have shown increased cardiac complications after WLI and chemotherapy...
  35. KSHV genome modification in KS tissue
    Erle S Robertson; Fiscal Year: 2013
    ..In the HIV positive immunocompromised patients, pleural effusion lymphoma (PELs), Kaposi's sarcoma (KS) and Multicentric Castleman's Disease (MCD) are common...
  36. Engineered imaging nanoparticles for real-time detection of cancer in the tumor b
    W David Lee; Fiscal Year: 2013
    ..These imaging agents are based upon the design of our lead candidate for sarcoma and breast cancer indications, LUM015, which has been approved by the FDA to start first-in-human clinical trials ..
  37. ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
    Lori Rink; Fiscal Year: 2013
    ..I will be mentored by Drs. Margaret von Mehren (Professor &Director, Sarcoma Program), Andrew K...
  38. In vivo model of hypoxia in Ewing Sarcoma
    Joanna B Kitlinska; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Ewing's sarcoma family of tumors (ESFT) is a group of highly aggressive malignancies, the treatment of which remains an unsolved clinical problem...
  39. Human Herpesvirus-8 Replication and Kaposi Sarcoma Response to Treatment
    Warren Phipps; Fiscal Year: 2013
    ..training program which will allow him to develop a career as an independent investigator in the field of Kaposi sarcoma (KS) and HIV-associated malignancies...
  40. Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom
    Vicente Notario; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Tumors of the Ewing's sarcoma family (ESFT) are solid, highly malignant neoplasms of the bone and soft tissues that most often affect children and adolescents, being the second most common bone ..
  41. Exploring Sarcoma Metastatic Potential
    KURT RICHARD WEISS; Fiscal Year: 2013
    ..He has worked with sarcoma research experts at the MD Anderson Cancer Center and the National Cancer Institute as well as the Universities ..
  42. K-Rta as a Novel SUMO and Epigenetic Regulator
    Yoshihiro Izumiya; Fiscal Year: 2013
    ..mechanisms, involving post-translation modification of chromatin proteins, in the life cycle of Kaposi's sarcoma herpesvirus (KSHV), which is an etiological agent of Kaposi's sarcoma (KS), an AIDS-associated malignancy...
  43. Pathogenic mechanisms of alveolar rhabdomyosarcoma
    MARGARET MARY CHOU; Fiscal Year: 2013
    ..Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma;of the various subtypes, ARMS carries the worst prognosis...
  44. Roles for TDP-43 and FUS in ALS Using Motor Neurons from Embryonic Stem Cells
    Dara Ditsworth; Fiscal Year: 2012
    ..Mutations in two DNA/RNA binding proteins, TAR DNA-binding protein (TDP-43) and Fused in Sarcoma (FUS) have recently been identified as primary causes of inherited ALS and have led to what is likely to be a ..
  45. Nuclear Export of Retroviral RNPs: Cytoplasmic fates determined in the nucleus
    REBECCA J KADDIS; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Rous sarcoma virus (RSV), the first tumor virus identified, has been the genesis for seminal discoveries in cancer biology and retrovirology, including oncogenes, reverse transcription, and ..
  46. Mechanisms of Tyrosine Kinase Inhibitor Resistance in GI Stromal Tumors
    Michael Heinrich; Fiscal Year: 2012
    ..provided by applicant): Gastrointestinal stromal tumors (GISTs), the most common type of adult soft tissue sarcoma, are diagnosed in approximately 5,000-10,000 Americans each year...
  47. Molecular library screen for suppressors of FUS proteinopathy
    Frank P Shewmaker; Fiscal Year: 2013
    ..Recently, the DNA/RNA-binding proteins FUS (Fused in Sarcoma) and TDP-43 (TAR DNA-binding protein) were implicated in these diseases...
  48. Transcriptional control mechanisms by ETS factors
    Barbara J Graves; Fiscal Year: 2013
    ..These regulatory proteins play central roles in a variety of human cancers, including prostate cancer, Ewings sarcoma and various leukemias...
  49. Cellular Protein Involved in Trafficking of HIV-1
    Carol A Carter; Fiscal Year: 2013
    ..Gag proteins with domains derived from HIV- 1 Gag, whose budding is dependent on the calcium machinery and avian sarcoma virus Gag, whose release is not, will be used to identify the key determinants...
  50. MANIPULATION OF KINASE ACTIVITY BY KSHV LANA
    S Diane Hayward; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Kaposi's sarcoma associated herpesvirus (KSHV) is associated with the endothelial lesion Kaposi's sarcoma and the B cell malignancies primary effusion lymphoma and multicentric Castleman&..
  51. Understanding the mechanism of KSHV latent DNA replication
    Subhash C Verma; Fiscal Year: 2011
    ..Kaposi's sarcoma associated Herpesvirus (KSHV) predominantly infects B cells and endothelial cells and persists indefinitely with ..
  52. Phase I Study of IMC-A12 in Combination with Temsirolimus
    Aung Naing; Fiscal Year: 2010
    ..The drug combination tested in this protocol has the promise of providing broad applicability for tumor types such as breast, sarcoma and pancreas in subsequent phase II trials.
  53. KSHV-Ori-Lyt-Dependent DNA Replication
    Yan Yuan; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8 (HHV-8), is a human pathogen responsible for several AIDS associated malignancies including Kaposi's ..
  54. Developing in vivo and in vitro Models for ALS Caused by Mutant FUS
    Xugang Xia; Fiscal Year: 2011
    ..A recent advance in ALS research is the discovery of pathogenic mutations in the Fused in Sarcoma (FUS) gene in ALS. FUS is a highly conserved ribonucleoprotein encoded by the FUS gene of 15 exons...
  55. Transport and Insertion of Outer Membrane Proteins
    Sangita Sinha; Fiscal Year: 2009
    ..virus which causes infectious mononucleosis and malignant tumors of lymphoid and epithelial tissues and Kaposi Sarcoma virus, which causes Kaposi sarcoma tumors, especially among immunocompromised individuals such as AIDS patients ..
  56. Dissecting sarcoma complexity via innovative microRNA and informatics approaches
    Dimitrios Spentzos; Fiscal Year: 2012
    ..in cancer genomics, and recently assumed an independent translational appointment with a clinical focus in sarcoma. Sarcoma is a disease with a substantial clinical and biologic complexity and high incidence in younger ..
  57. Anti-viral IL6 approach to mitigate KSHV-related disease
    Scott W Wong; Fiscal Year: 2012
    ..RRV, like Kaposi's sarcoma-associated herpesvirus (KSHV), encodes an interleukin-6 (IL-6) homologue, which is thought to be a necessary ..
  58. The role of cell surface heat shock protein 90 in KSHV pathogenesis
    MICHAEL ROBERT DEFEE; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Kaposi sarcoma (KS) is the most common cancer arising in HIV- infected individuals with as many as 60% of cases involving the oral cavity...
  59. Rhesus HHV-8 homologue in AIDS-related malignancies
    Scott W Wong; Fiscal Year: 2013
    ..recently identified to be associated with cancer in humans in 1995 is human herpesvirus 8 (HHV8)/Kaposi's sarcoma-associated herpesvirus (KSHV)...
  60. Genome Persistence of KSHV
    Erle S Robertson; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Kaposi's sarcoma associated herpes virus (KSHV/HHV-8) is the second identified gammaherpesvirus associated with at least 3 major proliferative diseases...
  61. DNA sensors and associated signaling pathways in the innate immune response
    Katherine A Fitzgerald; Fiscal Year: 2013
    ..evidence also indicates that IFI16 can form an inflammasome in responses to nuclear sensing of Kaposi's Sarcoma Herpes Virus infection...
  62. An Animal Model for Kaposi's Sarcoma
    Christopher Parsons; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Kaposi's sarcoma (KS) is a multicellular, angiogenic tumor arising in the setting of immunosuppression, including AIDS and solid organ transplantation...
  63. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2009
    Kaposi's sarcoma (KS) develops as a vascular proliferate process in response to infection of endothelial cells or their precursors with HHV-8...
  64. Antiretroviral Therapy of AIDS-Related Kaposi's Sarcoma in Africa
    Jeffrey Martin; Fiscal Year: 2009
    ..In sub-Saharan Africa, the intersection between the HIV epidemic and the endemic nature of Kaposi's sarcoma-associated herpesvirus (KSHV) infection has caused Kaposi's sarcoma (KS) to become the most common ..
  65. Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV
    Richard Carvajal; Fiscal Year: 2009
    Despite potentially curative therapies, the majority of patients with treated metastatic sarcoma die as a result of subsequent disease relapse...
  66. PF-8 AND POL-8 OF KSHV AS TARGETS OF VIRAL DNA SYNTHESIS
    Robert Ricciardi; Fiscal Year: 2001
    DESCRIPTION: (Adapted from Applicant's Abstract) Kaposi's sarcoma-associated herpesvirus (KSHV) is the apparent etiological cause of Kaposi's sarcoma, a neoplasm of frequent occurrence in HIV infected individuals...
  67. Engineered imaging nanoparticle for realtime detection of cancer in the tumor bed
    W David Lee; Fiscal Year: 2011
    ..agent and detection system for labeling and real- time detection of residual cancer in the tumor bed during sarcoma resection surgery that will be quickly adopted by surgeons/hospitals because it can eliminate or significantly ..
  68. KSHV TRANSFORMATION AND ANGIOGENESIS IN KAPOSIS SARCOMA
    Ethel Cesarman; Fiscal Year: 2001
    Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8 (HHV 8), is invariably present in Kaposi's sarcoma (KS) lesions where it has been localized in the endothelial cells as well as in the spindle cells, which are ..
  69. YK-4-279 specifically targets ETS family fusion-protein cancers in clinical trial
    Jeffrey A Toretsky; Fiscal Year: 2010
    ..over the past eight years supporting direct targeting of an ideal cancer target in the very rare Ewing's Sarcoma. This ideal cancer target originates from a tumor-specific chromosomal translocation only present in the tumor ..
  70. KAPOSIS SARCOMA ASSOCIATED VIRUS IN AIDS/LYMPHOMAS
    Ethel Cesarman; Fiscal Year: 1999
    The principal objective of the studies proposed here is to determine the role of the recently identified Kaposi's sarcoma-associated herpesvirus (KSHV) in the pathogenesis of AIDS-associated body cavity based lymphomas (AIDS-BCBLs)...
  71. BIOLOGICAL STUDIES IN KAPOSI'S SARCOMA
    PHILIP BROWNING; Fiscal Year: 2000
    ..abstract) Since early in the AIDS epidemic, HIV-infected individuals have higher incidence rates of Kaposi's sarcoma (ICS) than HIV-1 infected age-matched controls...
  72. CHEMO/IMMUNOTHERAPY FOR HIGH RISK EWINGS SARCOMA
    Eugenie Kleinerman; Fiscal Year: 2001
    DESCRIPTION: (adapted verbatim from the investigator's abstract) Patients with Ewing's sarcoma family of tumors who are at high-risk for relapse are those with metastic disease at diagnosis, with a primary tumor of the humerus, femur or ..